

ABSTRACT OF THE DISCLOSURE

The invention concerns a method of identifying a substance suitable for use in the treatment of a leukocyte-associated inflammatory disease which modulates the activity of a polypeptide encoded by the human transient receptor potential 6 gene. The method involves combining a candidate substance with the polypeptide and measuring the effect of the candidate substance on the activity of the polypeptide.